Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active, and competitive antagonist of neuronal nAChRs. Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC50s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities.

Product information

CAS Number: 29734-68-7

Molecular Weight: 356.25

Formula: C16H22BrNO3

Chemical Name: (1S,16S)-16-methoxy-5-oxa-10-azatetracyclo[8.7.0.0¹,¹³.0²,⁷]heptadeca-2(7),13-dien-4-one hydrobromide

Smiles: Br.CO[C@@H]1C[C@@]23C(CCN2CCC2COC(=O)CC3=2)=CC1

InChiKey: GFIGWAJEIMHJJB-LINSIKMZSA-N

InChi: InChI=1S/C16H21NO3.BrH/c1-19-13-3-2-12-5-7-17-6-4-11-10-20-15(18)8-14(11)16(12,17)9-13;/h2,13H,3-10H2,1H3;1H/t13-,16-;/m0./s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 8 mg/mL (22.46 mM; Need ultrasonic and warming). H2O : 35 mg/mL (98.25 mM; Need ultrasonic and warming).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

Dihydro-Beta-Erythroidine hydrobromide (DHβE hydrobromide; 10 nmol/0.5 μL) is infused into the respective areas prior to a systemic nicotine injection (0.2 mg/kg; SC). DHβE infused into the ventral tegmental area (VTA), nucleus accumbens (NAcc), or infralimbic (IL) cortex, but not prelimbic (PrL) cortex, attenuated nicotine-enhanced responding for a conditioned reinforcer (CRf). The co-administration of Dihydro-Beta-Erythroidine hydrobromide (5.0 mg/kg; s.c) with nicotine (0.2 and 0.4 mg/kg; s.c.) prevents the development of conditioned taste aversions (CTAs).

Products are for research use only. Not for human use.